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A B S T R A C T
Myositis ossiﬁcans is deﬁned as a self-limiting pseudotumor composed of reactive hypercellular ﬁbrous tissue
and bone.
USP6 rearrangements have been identiﬁed as a consistent genetic driving event in aneurysmal bone cyst and
nodular fasciitis. It is therefore an integral part of the diagnostic workup when dealing with (myo)ﬁbroblastic
lesions of soft tissue and bone. Two cases of myositis ossiﬁcans with USP6 rearrangement were published so far.
We determine herein the incidence of USP6 rearrangement in myositis ossiﬁcans using USP6 ﬂuorescence in
situ hybridization analysis (FISH). Of the 11 cases included, seven patients were female and four were male. Age
ranged from 6 to 56 years (mean 27 years). Lesions were located in the thigh (n= 5), knee (n= 1), lower leg
(n=1), lower arm (n=1), perineum (n= 1), gluteal (n= 1) and thoracic wall (n= 1).
All assessable cases except one (8/9) showed rearrangement of USP6 providing evidence that myositis os-
siﬁcans is genetically related to nodular fasciitis and aneurysmal bone cyst.
1. Introduction
Myositis ossiﬁcans is deﬁned as a self-limiting pseudotumor com-
posed of reactive hypercellular ﬁbrous tissue and bone. This rapid
growing and involuting lesion is mostly located in the skeletal muscle of
the extremities or limb girdles of young patients and is usually inter-
preted as a posttraumatic lesion [1,2]. However, its cause is debated
since its early description in 1892 [3].
The clinical characteristics depend on the developmental stage; the
early phase is characterized by a painful swelling and within 6 weeks
after onset it becomes more circumscribed and ﬁrm. Eventually, it
evolves into a painless, well-demarcated hard lump with a diameter of
ca. 3 to 6 cm [1].
Radiographically, soft tissue fullness is observed in the early stage.
Subsequently, calciﬁcation becomes apparent with patchy and irregular
densities maturing after approximately 6 weeks into a bony periphery
with a radiolucent center [1].
The histological ﬁndings reﬂect those of the clinical symptoms and
radiology. The early stage is characterized by nodular fasciitis-like
features and additional development of woven bone terminally showing
a prominent zonation with cancellous bone at the periphery [1,2]. In
addition, entrapment of muscle ﬁbers is often observed.
Since USP6 rearrangement was identiﬁed as a consistent genetic
driving event, initially in aneurysmal bone cyst (ABC) and later in
nodular fasciitis as well, it is an integral part of diagnostic workup when
dealing with (myo)ﬁbroblastic lesions of soft tissue and bone [4-9].
Interestingly, two cases of myositis ossiﬁcans containing USP6 re-
arrangements were published by Sukov et al. and classiﬁed as being
aneurysmal bone cysts of soft tissue [10].
We therefore set out to determine the incidence of USP6 re-
arrangement in myositis ossiﬁcans using USP6 ﬂuorescence in situ hy-
bridization analysis (FISH).
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2. Material and methods
The cases were retrieved from the authors' (referral) ﬁles. Clinical
details were obtained from the referring physicians. The study was
conducted in accordance with the Code of Conduct of the Federation of
Medical Scientiﬁc Societies.
In all cases the tissue was ﬁxed in 4% buﬀered formalin, routinely
processed including decalciﬁcation, if needed, and embedded in par-
aﬃn; 2–4 μm thick sections were stained with hematoxylin and eosin.
USP6 FISH detection was performed on paraﬃn sections of 4 μm.
Slides were mounted and dried for 45min at 55 °C. They were depar-
aﬃnized in xylene for 5min, rehydrated in ethanol (99,5%) and de-
mineralized water. Pretreatment with 10 mM Sodiumcitrate (pH=6.0)
at 96 °C for 10min followed and after cooling down, rinsing in demi-
neralized water. Slides were rinsed with 0,01M HCL for 5min and cells
were digested by 200 U/ml pepsin (0,01 M HCL) for 15min at 37 °C. To
remove pepsin, slides were rinsed 3× shortly with 0,01 M HCI and
rinsed with PBS. Slides were ﬁxated in 1% formaldehyde/PBS for 5min.
After that, slides were rinsed shortly with PBS and demineralized water
and ﬁnally dehydrated in increasing ethanol series and are dried.
For the ISH staining, 10 μl USP6 (Kreatech, KBI-00094 split probe,
Leica, Rijswijk, The Netherlands) was applied per pre-treated slide. The
probe incubated area were covered with a cover glass and sealed with
photo glue. The slides were denaturated at 80 °C for 10min and hy-
bridization overnight at 37 °C. After hybridization the slides were wa-
shed in 2xSSC at 42 °C for 5min to remove the cover glass, washed for
1× 1min and 1×2min in 2xSSC-NP40 3% washbuﬀer at 73 °C and
rinsed with 2xSSC for 5min (covered). Slides were dehydrated again in
increasing ethanol series to demineralized water and were dried. Slides
were covered with Vectashield mounting medium with DAPI (Vector,
Brunschwig, Amsterdam, The Netherlands) and stored at 4 °C.
USP6 signals were scored by two independent experienced techni-
cians and considered positive if at least 20% of the 50 counted cells
showed split signals. Slides were scored using a Leica DM4000 (Leitz)
ﬂuorescence microscope with a Leica DFC310 FX camera and LAS AF
software.
As positive control, we included 10 samples of nodular fasciitis and
10 aneurysmal bone cysts.
3. Results
Clinical and FISH results are summarized in Table 1. Of the 11
patients included, seven were female and four were male. The age
ranged from 6 to 56 years (mean 27 years). Lesions were located in the
thigh (n= 5), knee (n=1), lower leg (n=1), lower arm (n=1),
perineum (n=1), gluteal (n= 1) and thoracic wall (n= 1).
By computed tomography, coronal reconstruction, bone window, a
diﬀuse swelling of the proximal rectus femoris muscle with faint per-
ipheral calciﬁcations was seen (Case 8) (Fig. 1). On MRI, TSE T2-
weighted coronal image with fat saturation of the same patient showed
a sharply delineated lesion with inhomogeneous high signal intensity
with peripheral low signal intensity (Fig. 2).
Six patients underwent resection, in the remaining patients, only a
biopsy was taken until now.
Grossly, all lesions were located in the voluntary muscle. The re-
section specimens showed an ill-deﬁned, ﬁrm nodule with gray-white
appearance and gritty areas. Small cystic spaces were seen in one case
(Case 3).
Microscopically, the lesions showed an inﬁltrative growth with
entrapped muscle ﬁbers. Nodular fasciitis-like areas with tissue culture-
like myoﬁbroblasts intermingled with woven bone maturating periph-
erally were seen in all cases. There was osteoblast rimming without
atypia. Scattered around, osteoclastic giant cells in a varying number
were observed (Fig. 3). ABC-like pseudocystic spaces were present in
only one case (Case 3, Fig. 4).
Using FISH, USP6 rearrangement were shown in eight out of 11
cases with one case being negative (< 10% signals) (Fig. 5). Two cases
Table 1
Clinical and FISH results.
Case # Sex/age Site USP6 FISH
(% of nuclei)
1 f/24 Perineum >50
2 f/19 Lower leg 34
3 m/28 Lower arm failed
4 m/44 Thoracic wall 20
5 m/25 Thigh 25
6 f/17 Thigh 50
7 f/38 Thigh 30
8 f/32 Thigh 50
9 f/8 Knee 25
10 m/56 Thigh <10
11 f/6 Gluteal Failed
f, female; m, male.
Fig. 1. By CT, a diﬀuse swelling of the proximal rectus femoris muscle with faint per-
ipheral calciﬁcations was seen (Case 8).
Fig. 2. On MRI, a sharply delineated lesion with inhomogeneous high signal intensity
with peripheral low signal intensity was observed (Fig. 2).
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repeatedly failed for analysis, probably related to decalciﬁed end stage
areas (Table 1).
4. Discussion
Nodular fasciitis, myositis ossiﬁcans and aneurysmal bone cyst
share clinicopathologic characteristics. First, they mainly occur in
young patients. Second, the soft tissue lesions, nodular fasciitis and
myositis ossiﬁcans, are of short duration with rapid growth and sec-
ondary involution, also called transient neoplasms [1,2,5,11,12].
All three entities are microscopically related by the presence of
bland looking tissue culture like (myo)ﬁbroblastic cells. Osteoclasts are
mainly present in the two bone forming lesions and secondary pseu-
docystic changes are possible in all three neoplasms although they are
most prominent in aneurysmal bone cyst, as expected. In exceptional
cases, nodular fasciitis shows metaplastic bone formation, called fas-
ciitis ossiﬁcans [1,2,11,12].
Another neoplasm clinicopathologically related to aneurysmal bone
cyst is giant cell lesion of small bones [13].
The most convincing argument for these conditions forming a
spectrum rather than distinct entities is the presence of USP6 re-
arrangement [4,5,7,8,13]. This is supported by our study with re-
arrangement in eight out of nine cases (89%).
Interestingly, the presence of USP6 rearrangement has also been
described in a subset of cellular ﬁbromas of the tendon sheath, retro-
spectively assigned to nodular fasciitis [14].
USP6 (ubiquitin speciﬁc protease) is one of deubiquinating enzymes
involved in several cellular processes as intracellular traﬃcking, pro-
tein turnover, inﬂammatory signaling, and cell transformation [7,11]. It
has been shown that the USP6 fusion genes result in USP6 over-
expression due to promoter switch. This in turn leads to tumorigenesis,
osteoblastic maturation, osteolysis, inﬂammation and neovascularisa-
tion [7]. Jak1-STAT3, c-Jun/AP-1 and Wnt signaling are the known
involved pathways [15,16,18].
There is a variety of fusion partners described in ABC which are
mainly functionally assigned to the ﬁbroblastic-osteoblastic lineage
(CDH11,TRAP150, ZNF9, OMD, COL1A1, RUNX2, PAFAH1B1, CTNNB1,
SEC31A, E1F1, FOSL2, STAT3) [7,17]. The common USP6 fusion
partner of nodular fasciitis is MYH9, normally expressed in sub-
cutaneous ﬁbroblasts [7]. Recently found novel fusion genes are
RRBP1, CALU, MIR22HG, SPARC, THBS2, COL6A2 and CTNNB1. The
latter in overlap with aneurysmal bone cyst [8].
What fusion genes are present in myositis ossiﬁcans remain to be
elucidated as USP6 FISH has been performed. From the literature it is
known that one of the USP6 rearranged cases of myositis ossiﬁcans
showed a fusion with COL1A1. The other case was negative for CDH11
[7,10].
The most important entity that myositis ossiﬁcans must be dis-
tinguished from is extraskeletal osteosarcoma. This very rare tumor
shows histologically atypical neoplastic osteoblast-like cells with pleo-
morphic nuclei. The typical zonation of bone is absent [1].
Other benign ﬁbro-osseous conditions which could be considered in
the diﬀerential diagnosis are subungual exostosis, ﬂorid reactive peri-
ostitis, bizarre parosteal osteochondromatous proliferation, and ﬁbro-
osseous pseudotumor of digits. However, the clinicopathological fea-
tures are diﬀerent with occurrence usually in ﬁngers and toes and ab-
sence of the bone zonation pattern [1].
Simple excision is the optimal treatment of myositis ossiﬁcans and
recurrence is exceptional [2].
In conclusion, we have identiﬁed USP6 rearrangements in a series of
myositis ossiﬁcans cases. We therefore argue that this entity belongs to
the group of clonal transient neoplasms also including nodular fasciitis
and aneurysmal bone cyst.
Fig. 3. Classical features of myositis ossiﬁcans showing tissue culture-like myoﬁbroblasts
intermingled with woven bone were seen in all cases.
Fig. 4. ABC-like pseudocystic spaces were present in Case 3.
Fig. 5. Using FISH break apart signals of USP6 were seen in 8/9 cases demonstrating
rearrangement.
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